Please login to the form below

Not currently logged in
Email:
Password:

ceritinib

This page shows the latest ceritinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer

Alecensa saw sales double to reach around $385m in 2017, and its ascendency also seems to have taken its toll on Novartis’second-generation drug Zykadia (ceritinib).

Latest news

More from news
Approximately 5 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination with BMS's PD-1 immune checkpoint inhibitor nivolumab [Opdivo].

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics